MAPT and Alzheimer disease: These top candidates were then used to create a classification model with high accuracy (AUC = 0.94), claiming that these autoantibodies could distinguish AD from other neurodegenerative diseases and showed better performance than Aβ and tau protein concentrations in CSF in predicting cognitive decline.